Advertisement

A treatment for irritable bowel syndrome developed by Cambridge-based Ironwood Pharmaceuticals Inc. (Nasdaq: IRWD) and partner Forest Laboratories Inc. (NYSE: FRX), of New York, has achieved positive results in a second Phase 3 clinical trial, meeting both primary and secondary endpoints.

Linaclotide, the treatment of irritable bowel syndrome with constipation (IBS-C), was found to have improved results in patients taking the drug candidate, over those taking placebo, in measures of abdominal pain, abdominal discomfort, bloating and bowel symptoms.

SOURCE

Advertisement
Advertisement